How experienced directors and operators help build credibility in emerging biotech categories When Eli Lilly agreed to acquire AtaiBeckley for up to $2.8 billion, most of the coverage focused on the science and the price. Both matter. But the deal also signals something larger than a single transaction. It follows AbbVie’s move into the space months earlier, and analysts already expect additional large drugmakers…